The accessa Cholesterol Panel is intended for in vitro, quantitative determination of Total Cholesterol, HDL-Cholesterol, Triglycerides and calculated LDL-Cholesterol in dried micro-serum samples ("Cholesterol Panel"). Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis and various liver and renal diseases. The Cholesterol Panel is not intended for use on neonates. LDL-Cholesterol cannot be determined where the triglycerides value is greater than 400 mg/dL.

Device Description

The accessa Cholesterol Panel incorporates the use of two separately regulated products.

The Home Access Micro Serum Specimen (MSS) Collection Kit (a Class I Medical Device listed with the FDA effective February 19, 2003, and manufactured under the Quality System Regulations) and
The Home Access Health Corporation (HAHC) Clinical Chemistry . Laboratory Lipid Profile Test Methods (Regulated under CLIA number 14D0981820).

The Home Access Micro Serum Specimen Collection Kit ("MSS collection kit"), (Class I Medical Device CFR 21 Part 864.3250, registered February 19, 2003) is intended to facilitate in vitro diagnostic laboratory testing of fingerstick blood samples for a variety of clinical chemistry assays. This MSS collection kit includes a collection cassette, storage pouch and prepaid mailer along with all the materials necessary to self-collect a capillary blood sample into the blood collection/transportation cassette. The cassette is packaged along with patient/customer information and transported to the certified clinical laboratory for lipid profile testing. In its final configuration, the accessa Cholesterol Panel kit is comprised of:

. Blood collection/transportation cassette
Sample Return Pouch with Desiccant .
2 Safety lancets ●
Gauze pad .
Adhesive bandage .
. Instructions for use
Brochure: "What you need to know to keep your heart healthy" .
Prepaid US Mail return mailer .
Informed Consent Form .
Outer Box .

The patient/customer follows the directions to self-collect a capillary blood sample (approximately 100 micro liters), package and mail the sample to a certified clinical laboratory for analysis using FDA-cleared reagent and analysis systems. Once the dried sample is received in the laboratory, it is accessioned, labeled and eluted into a usable serum sample. Once eluted, the sample can be assaved as a diluted serum sample using US FDA-cleared reagents. All testing is done via the Roche Cobas Mira Plus chemical analyzer and utilizes the software approved for use in the testing instrument (K920402). The clinical laboratory is located at Home Access Health Corporation.

AI/ML Overview

Here's an analysis of the provided text regarding the acceptance criteria and study for the accessa Cholesterol Panel, presented in the requested format:

1. Table of Acceptance Criteria and Reported Device Performance

The provided 510(k) summary (K063852) does not explicitly state specific numeric acceptance criteria for the accessa Cholesterol Panel. Instead, it makes a general claim of "substantial equivalence" to predicate devices and venous (serum) results.

However, the key performance claim is related to comparability with venous samples. Therefore, the reported performance is the qualitative statement of "substantial equivalence."

Criterion	Acceptance Criteria	Reported Device Performance
Comparability of self-collected capillary samples to venous (serum) results for: - Total Cholesterol - HDL-Cholesterol - Triglycerides - Calculated LDL-Cholesterol	Not explicitly stated (implied clinical equivalence to predicate and venous results)	"Results of clinical trials show that self-collected capillary samples onto the accessa Blood Collection Cassette provide results that are substantially equivalent to venous (serum) results for Total Cholesterol, HDL-Cholesterol and Triglycerides when analyzed using Home Access Health Laboratories modified analytical methods." "The results of clinical trials demonstrated that self-collected capillary samples, tested using the HAHC proprietary testing algorithm, are substantially equivalent to venous (serum) results for Total Cholesterol, HDL-Cholesterol, Triglycerides and calculated LDL-Cholesterol."

2. Sample Size Used for the Test Set and Data Provenance

Sample Size: The document does not specify a precise sample size for the clinical study. It mentions subjects, but not the number of them.
Data Provenance: The formal clinical study was conducted independently by the LMARC Research Center in Louisville, KY, USA. The data is prospective, as samples were collected specifically for the study ("between March 2006 and May 2006").

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

There is no mention of experts being used to establish ground truth in the traditional sense of a consensus or adjudication panel. The "ground truth" for the performance comparison was established by comparing the results from the self-collected capillary samples against venipuncture samples (serum) from the same subjects. These venipuncture samples were then analyzed using FDA-cleared reagent and analysis systems at the certified clinical laboratory.

4. Adjudication Method for the Test Set

Not applicable. There was no expert adjudication method described for establishing ground truth, as ground truth was based on venipuncture serum samples analyzed by established laboratory methods.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No, this was not a Multi-Reader Multi-Case (MRMC) comparative effectiveness study. This device is a sample collection and transport system intended for laboratory analysis, not an interpretative diagnostic tool requiring human reader comparison.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Yes, in a sense. The core of the performance evaluation is the performance of the "accessa Cholesterol Panel" which includes the collection kit and the HAHC Clinical Chemistry Laboratory Lipid Profile Test Methods. The comparison is between the results obtained from the collected capillary samples (processed by the HAHC lab) and the venipuncture serum samples (also processed by standard lab methods). While humans are involved in laboratory analysis, the "device" itself (collection and transport) is evaluated based on the analytical results produced by the laboratory method, not on human interpretation of an image or data. The "proprietary algorithm" mentioned in the summary refers to the laboratory's internal processing and analytical methods for the eluted sample, not an AI algorithm for diagnosis.

7. The Type of Ground Truth Used

The ground truth used was venipuncture serum sample results obtained from "FDA-cleared reagent and analysis systems" using standard laboratory test methods (Total Cholesterol: Amresco Cholesterol Reagent Assay K891922, HDL Cholesterol: Wako L-Type HDL-C Reagent Assay K801834, Triglycerides: Roche Triglycerides K801298). This can be classified as a form of reference standard laboratory testing.

8. The Sample Size for the Training Set

The document does not explicitly mention a separate "training set" or its sample size. The description focuses on the "clinical study" which served as the validation for the device performance. The "proprietary algorithm" mentioned is likely the standard laboratory's analytical method, which would have been established and validated through internal lab procedures, not a distinct "training set" in the machine learning sense.

9. How the Ground Truth for the Training Set Was Established

As no specific "training set" for a machine learning algorithm is described, this question is not directly applicable. The "proprietary algorithm" refers to the HAHC Clinical Chemistry Laboratory Lipid Profile Test Methods. The ground truth for validating these laboratory methods would have been established through standard laboratory quality control, calibration, and validation procedures, typically against certified reference materials or established gold-standard methods.

Summary

{0}------------------------------------------------

K063852

510(k) Summary

Submitter's Name, Address, Contact

Contact Person:	Home Access Health Corporation ("HAHC")2401 W. Hassell Rd. Suite 1510Hoffman Estates, IL 60169Phone 1.847.781.2500Fax 1.847.781.2560Mary Vogt, Vice President
Date Prepared:	21 December 2006
Device Name:
Proprietary Name:	accessa Cholesterol Panel
Common Name:	Capillary blood self-collection and transportationsystem for Total Cholesterol, HDL-Cholesterol,Triglycerides, and Calculated LDL-Cholesterol.
Classification Names:	Capillary blood self-collection and transportsystem for the in-vitro testing of:Cholesterol (21CFR 862.1175)HDL Cholesterol (21CFR 862.1475)Triglycerides (21CFR 862.1705)LDL Cholesterol (21CFR 862.1475)
Predicate Devices:	Predicate Device: Safe At Home Cholesterol Profile K012221manufactured by BIOSAFE Laboratories, Inc.
Predicate Test Methods:	Total Cholesterol: Amresco Cholesterol Reagent Assay K891922 HDL Cholesterol: Wako L-Type HDL-C Reagent Assay K801834 Triglycerides: Roche Triglycerides K801298
Device Description:	The accessa Cholesterol Panel incorporates the use of two separately regulated products.The Home Access Micro Serum Specimen (MSS) Collection Kit (a

The Home Access Micro Serum Specimen (MSS) Collection Kit (a Class I Medical Device listed with the FDA effective February 19, 2003, and manufactured under the Quality System Regulations) and
The Home Access Health Corporation (HAHC) Clinical Chemistry . Laboratory Lipid Profile Test Methods (Regulated under CLIA number 14D0981820).

{1}------------------------------------------------

Collection Kit Description:

. Blood collection/transportation cassette
Sample Return Pouch with Desiccant .
2 Safety lancets ●
Gauze pad .
Adhesive bandage .
. Instructions for use
Brochure: "What you need to know to keep your heart healthy" .
Prepaid US Mail return mailer .
Informed Consent Form .
Outer Box .

Testing Service Description:

. The patient/customer follows the directions to self-collect a capillary blood sample (approximately 100 micro liters), package and mail the sample to a certified clinical laboratory for analysis using FDA-cleared reagent and analysis systems. Once the dried sample is received in the laboratory, it is accessioned, labeled and eluted into a usable serum sample. Once eluted, the sample can be assaved as a diluted serum sample using US FDA-cleared reagents. All testing is done via the Roche Cobas Mira Plus chemical analyzer and utilizes the software approved for use in the testing instrument (K920402). The clinical laboratory is located at Home Access Health Corporation.

Indications for Use:

{2}------------------------------------------------

Panel is not intended for use on neonates. LDL-Cholesterol cannot be determined where the triglycerides value is greater than 400 mg/dL.

Comparison to Predicate Devices:

The accessa Cholesterol Panel is substantially equivalent to the Safe At Home Cholesterol Profile K012221 manufactured by BIOSAFE Laboratories, Inc, as well as the laboratory methods listed below. Both the accessa Cholesterol Panel and the Safe At Home Cholesterol Profile kits provide the patient a method to collect a sample at home, mail it to a clinical laboratory, and later receive a report showing Total Cholesterol, HDL, Triglycerides, and Calculated LDL-Cholesterol. The only significant difference is the accessa Cholesterol Panel kit separates the serum from the blood whereas the Safe At Home kit collects whole blood.

The accessa Cholesterol Panel has technological characteristics that are substantially equivalent to that of the predicate devices listed above. The accessa Cholesterol Panel provides components that permit collection, storage, and transportation of a dried serum blood sample to a certified clinical laboratory for analysis using FDA-Cleared or Exempt laboratory reagent and analysis systems. All predicate and current kits are intended for the in vitro diagnostic laboratory determination of lipid profile analytes. The laboratory analyses used in conjunction with the accessa Cholesterol Panel utilize these test methods:

Total Cholesterol: Amresco Cholesterol Reagent Assay K891922 HDL Cholesterol: Wako L-Type HDL-C Reagent Assay K801834 Triglycerides: Roche Triglycerides K801298

Results of clinical trials show that self-collected capillary samples onto the accessa Blood Collection Cassette provide results that are substantially equivalent to venous (serum) results for Total Cholesterol, HDL-Cholesterol and Triglycerides when analyzed using Home Access Health Laboratories modified analytical methods.

Performance Studies:

The accessa Cholesterol Panel was validated using data from bench studies and from the formal clinical study conducted independently by LMARC Research Center in Louisville, KY between March 2006 and May 2006. The formal clinical study included self-collected capillary samples and professionally collected capillary samples using the blood collection/transportation cassette. Additionally, venipuncture samples were collected from each study subject to allow for comparison of serum lipid results with those obtained from capillary samples were expressshipped to the clinical laboratory. Each self-collected and each professionally-collected capillary sample was tested using the proprietary algorithm and results were compared to veniouncture sample results.

{3}------------------------------------------------

Conclusion:

The results of clinical trials demonstrated that self-collected capillary samples, tested using the HAHC proprietary testing algorithm, are substantially equivalent to venous (serum) results for Total Cholesterol, HDL-Cholesterol, Triglycerides and calculated LDL-Cholesterol. Analysis of data from both clinical and non-clinical testing shows that the accessa Cholesterol Panel is as safe and effective as the predicate device(s) and has no new indications for use.

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or body. The text "DEPARTMENT OF HUMAN SERVICES - USA" is arranged in a circular pattern around the bird-like figure.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Home Access Health Corporation c/o Ms. Karen L. Hanson Director, Regulatory Affairs/Quality Assurance 2401 West Hassell Road, Suite 1510 Hoffman Estates, IL 60169

NOV 0 9 2007

Re: K063852 Trade/Device Name: accessa Cholesterol Panel Regulation Number: 21 CFR 8862.1675 Regulation Name: Blood specimen collection device Regulatory Class: Class II Product Code: JKA, LBS, JGY, CHH Dated: October 30, 2007 Received: October 31, 2007

Dear Ms. Hanson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{5}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to 1 legally marketed predicate device results in a classification for your device and thus, perroits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M. Cooper, M.S., D.v.M.

Yéan M. Cooper, M.S., D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

Indications for Use

510(k) Number (if known):

Device Name: accessa Cholesterol Panel

Indications For Use:

Prescription Use X AND/OR (Part 21 CFR Subpart D)

Over-the-Counter Use X (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Casolf Benson

Sign-Off

ice of In Vitro Diagnostic Device . Juation and Safety

Page 1 of 1

K063852

Regulation Number and Section

§ 862.1675 Blood specimen collection device.

(a)
Identification. A blood specimen collection device is a device intended for medical purposes to collect and to handle blood specimens and to separate serum from nonserum (cellular) components prior to further testing. This generic type device may include blood collection tubes, vials, systems, serum separators, blood collection trays, or vacuum sample tubes.(b)
Classification. Class II.